Status:
COMPLETED
Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis
Lead Sponsor:
Pfizer
Conditions:
Ankylosing Spondylitis
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this observational study is to determine the incidence of response in patients with predictive factors of major clinical response in active ankylosing spondylitis (AS) in patients who...
Detailed Description
A sample size of 240 patients, 120 of them exposed and 120 not exposed to factors of response. Sample will be obtain from all the consecutive patients attending the rheumatology settings included in t...
Eligibility Criteria
Inclusion
- Patients diagnosed of active AS who will start anti-TNF therapy following standard clinical practice as per summary of product characteristics doses.
- \>18 years, both genders, any disease duration
- Signature of informed consent
Exclusion
- Previous treatment with biological therapies
- Active tuberculosis infection (local guidelines for appropriate screening and treatment of tuberculosis in the setting of anti-TNF therapy must be followed)
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT00900796
Start Date
March 1 2009
End Date
May 1 2011
Last Update
June 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Madrid, Madrid, Spain, 28006